CM
HRMY icon

Capital Management’s Harmony Biosciences HRMY Stock Holding History

Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Sell
285,500
-32,425
-10% -$1.02M 1.56% 29
2026
Q1 		$8.91M Buy
317,925
+36,204
+13% +$1.19M 1.52% 30
2025
Q4 		$10.5M Sell
281,721
-41,191
-13% -$1.35M 1.73% 25
2025
Q3 		$8.9M Sell
322,912
-29,654
-8% -$1.02M 1.4% 28
2025
Q2 		$11.1M Buy
352,566
+10,605
+3% +$341K 1.9% 25
2025
Q1 		$11.3M Buy
341,961
+1,001
+0.3% +$35.9K 1.97% 21
2024
Q4 		$11.7M Buy
340,960
+103,308
+43% +$3.55M 2.1% 19
2024
Q3 		$9.51M Sell
237,652
-2,388
-1% -$83.9K 1.69% 25
2024
Q2 		$7.24M Buy
240,040
+31,046
+15% +$934K 1.45% 31
2024
Q1 		$7.02M Buy
+208,994
New +$6.71M 1.34% 35

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Management's HRMY Position: Q2 2026 in Review

Capital Management reduced its Harmony Biosciences (HRMY) stake by 10% in Q2 2026, selling an estimated $1.02M and leaving 285,500 shares worth $10.4M. The position accounts for 1.56% of the portfolio, ranked #29.

Capital Management first reported a position in HRMY in Q1 2024 and has held it in 10 quarters since. The position peaked at $11.7M in Q4 2024. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Capital Management held 285,500 shares of Harmony Biosciences worth $10.4M as of Q2 2026.
  • Capital Management sold 32,425 Harmony Biosciences shares in Q2 2026, an estimated $1.02M.
  • Harmony Biosciences made up 1.56% of Capital Management's portfolio in Q2 2026, its #29 holding.
  • Capital Management first reported a position in Harmony Biosciences in Q1 2024 and has held it in 10 quarters since.
  • Capital Management's Harmony Biosciences position peaked at $11.7M in Q4 2024.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.